TX-FLUENCE-BY-OSRAM
23.11.2021 13:32:12 CET | Business Wire | Press release
Fluence by OSRAM (Fluence), a leading global provider of energy-efficient LED lighting solutions for commercial cannabis and food production, announced today it has partnered with White Lion Holdings , the leading consultant providing complete solutions for new and aspiring cannabis growers in South Africa.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211123005520/en/
Fluence’s South African partners include local distributor The Lamphouse, the largest supplier of specialized lamps in Africa with more than 40 years of experience in numerous specialty lighting sectors, and White Lion Holdings, a company offering complete cannabis growing solutions and consultancy, led by CEO Cornel van der Watt. Van der Watt has served at the forefront of developing cannabis markets in the U.S., Canada, the Netherlands and Lesotho, and has consulted extensively in Australia.
“Local partnerships are a key factor in delivering fast and reliable solutions to growers. Our stellar partners know the choice of lighting supplier is crucial to delivering consistent, high-quality yields premium clients in the northern hemisphere require,” said Timo Bongartz, Fluence’s general manager for Europe, the Middle East and Africa (EMEA). “Van der Watt chose to partner with Fluence and our local partner The Lamphouse based on his experience with Fluence’s superior LED products and valuable support in various jurisdictions where he has historically consulted cannabis growers.”
According to Prohibition Partners’ African Cannabis Report™ , by 2023, Africa’s legal cannabis industry could be worth more than $7.1 billion annually, with South Africa alone contributing an estimated $1.7 billion per year. The South African government’s recognition of the industry as a key to economic revival mirrors Prohibition Partners’ assessment—the cannabis industry represents the potential to create between 10,000 -25,000 job opportunities in a country with the highest unemployment rate in the world.
“The African cannabis market holds incredible potential and we know we’ve found the right partner in White Lion Holdings. We’re proud to collaborate with such a trusted brand and to support the growers who are revolutionizing the South African cannabis market,” Bongartz continues.
As the cannabis industry continues to gain traction throughout the country and continent, White Lion Holdings suggests growers will not only need innovative technology at their fingertips, but evidence-backed cultivation practices that yield high-quality crops, improved yields and consistent growth patterns.
“We’re thrilled to partner with Fluence and its local partner The Lamphouse,” said Van der Watt, who is currently consulting and managing four commercial operations throughout South Africa with other operations in the pipeline. “The cannabis plant is highly photosensitive. We prefer natural lighting and South Africa has an advantage in this regard with ample, good quality natural light. By choosing the location of the greenhouse well, one can get up to 11 hours of natural light for free. Then, we integrate supplemental lighting into the facility to optimize crop yield.”
The South African market is still in its infancy. Through its partnership with White Lion Holdings, Fluence lighting solutions have been implemented at pre-licensed and licensed cannabis greenhouse and indoor facilities throughout the country.
“I am testing various lighting solutions all the time, but those tests only reaffirm my partnership with Fluence and its local partner The Lamphouse given each company’s superior quality and valuable support. Thanks to consistent lighting, I have been able to surpass production targets. That is only possible with superior lighting,” Van der Watt added.
To achieve longevity in an industry that can quickly become crowded with new technologies and cultivation solutions, investors and growers must ensure they partner with experts in their respective fields who are purpose-built to support cultivators for the long-term.
“The Fluence system all but eliminates lighting as a variable and delivers a high return on investment. Optimizing the correct lighting strategy for the correct application and layout is one of the critical components to successful crop,” said Glenn Morris, CEO of The Lamphouse.
For more information on Fluence, visit www.fluence.science .
About Fluence by OSRAM
Fluence Bioengineering, Inc., a wholly-owned subsidiary of OSRAM, creates powerful and energy-efficient LED lighting solutions for commercial crop production and research applications. Fluence is a leading LED lighting supplier in the global cannabis market and is committed to enabling more efficient crop production with the world’s top vertical farms and greenhouse produce growers. Fluence global headquarters are based in Austin, Texas, with its EMEA headquarters in Rotterdam, Netherlands. For more information about Fluence, visit www.fluence.science .
About Cornel van der Watt and White Lion Holdings
With over 29 years of international, large scale cannabis cultivation experience under his belt, the White Lion Cornel van der Watt is in a class of his own. His knowledge of all aspects of the cannabis industry and his connections in the global cannabis community are unparalleled. He has also been at the forefront of the cannabis movement in South Africa since inception.
Every path he has walked in his professional and personal life has led him back to the cannabis industry. This path traces back to his qualification in chemical engineering, experience in scientific glassblowing, expertise in cultivation abroad and locally, studies in tissue cultivation, cloning and genetics, his community upliftment work as well as training and consulting.
While Cornel has become a scientist, a geneticist, a businessman and Cannabis Supremo, at the heart of his consultancy lies a deep and spiritual connection with the cannabis plant. For more information about White Lion Holding, visit https://www.whitelionholdings.co.za .
About The Lamphouse
Established in 1976, The Lamphouse is the largest supplier and distributor of specialized lamps in Southern Africa. Over the past 40 years, The Lamphouse has developed strategic relationships with suppliers and customers alike, providing lighting applications for horticulture, medical solutions, stage and studio, airfield, navigation and more. The company is headquartered in Johannesburg, South Africa, with additional offices in Cape Town and Durban. For more information about The Lamphouse, visit https://www.thelamphouse.co.za .
View source version on businesswire.com: https://www.businesswire.com/news/home/20211123005520/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
